Author:
Barata Pedro C.,Hong David S.
Publisher
Springer International Publishing
Reference47 articles.
1. Cleeland CS, Allen JD, Roberts SA, et al. Reducing the toxicity of cancer therapy: recognizing needs, taking action. Nat Rev Clin Oncol. 2012;9(8):471–8.
2. Le-Rademacher J, Hillman SL, Meyers J, Loprinzi CL, Limburg PJ, Mandrekar SJ. Statistical controversies in clinical research: value of adverse events relatedness to study treatment: analyses of data from randomized double-blind placebo-controlled clinical trials. Ann Oncol. 2017;28(6):1183–90.
3. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176–81.
4. Committee IS. ICH harmonised tripartite guideline. Clinical safety data management: definitions and standards for expedited reporting E2A. Step 4 version. Paper presented at International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 1994.
5. Institute NC. Common terminology criteria for adverse events (CTCAE). 2018.;
www.ctep.cancer.gov
. Accessed February 2018.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献